Erythropoietin a promising agent in the prevention of renal ischemia reperfusion injury

Mohammed Elshiekh ¹, Mehri Kadkhodaee ²^*, Behjat Seifi ²

¹ Department of Physiology, Faculty of Medicine, University of Dongola, Dongola, Sudan
² Department of Physiology, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, Iran

*Corresponding Author: Prof. Mehri Kadkhodaee, Email: kadkhodm@tums.ac.ir

Abstract

Erythropoietin (EPO) is an essential growth factor, which stimulates red blood cell formation by targeting hematopoietic colony forming unit (CFU-E) in the bone marrow. Erythropoietin stimulating agents (ESAs) such as recombinant human EPO (rHuEPO) are created by recombinant DNA technology in cell culture which is widely used for the treatment of anemia in chronic kidney disease (CKD). The potential protective effects of EPO against ischemia reperfusion (IR) injury have become manifest in kidney IR injury model and kidney replacement therapy. In our review, we discuss the evidence upholding EPO as essential agent in kidney IR injury and discuss the potential pathways by which it may confer this specific protection.

Keywords: Acute kidney injury, Erythropoietin, Chronic kidney disease, Erythropoietin receptor, Transplantation

Citation: Elshiekh M, Kadkhodaee M, Seifi B. Erythropoietin a promising agent in the prevention of renal ischemia reperfusion injury. Ann Res Antioxid. 2017;2(2):e01.